Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of sequential erlotinib plus docetaxel versus docetaxel alone as second-line treatment for progressive stage IV non-small cell lung cancer
2010-024592-77Phase 2Completed
- Sponsor
- CHU de Limoges
- Start
- Feb 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Sequential erlotinib + docetaxel with Docetaxel alone (2 arms). Primary endpoint: Progression-free survival at 15 weeks. Started Feb 2011; status: completed.
02
Drugs
erlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-024592-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024592-77.